Identification of hot spots in the variola virus complement inhibitor (SPICE) for human complement regulation.
Variola virus, the causative agent of smallpox, encodes a soluble complement regulator named SPICE. Previously, SPICE has been shown to be much more potent in inactivating human complement than the vaccinia virus complement control protein (VCP), although they differ only in 11 amino acid residues. In the present study, we have expressed SPICE, VCP, and mutants of VCP by substituting each or more of the 11 non-variant VCP residues with the corresponding residue of SPICE to identify hot spots that impart functional advantage to SPICE over VCP. Our data indicate that (i) SPICE is approximately 90-fold more potent than VCP in inactivating human C3b, and the residues Y98, Y103, K108 and K120 are predominantly responsible for its enhanced activity; (ii) SPICE is 5.4-fold more potent in inactivating human C4b, and residues Y98, Y103, K108, K120 and L193 mainly dictate this increase; (iii) the classical pathway decay-accelerating activity of activity is only twofold higher than that of VCP, and the 11 mutations in SPICE do not significantly affect this activity; (iv) SPICE possesses significantly greater binding ability to human C3b compared to VCP, although its binding to human C4b is lower than that of VCP; (v) residue N144 is largely responsible for the increased binding of SPICE to human C3b; and (vi) the human specificity of SPICE is dictated primarily by residues Y98, Y103, K108, and K120 since these are enough to formulate VCP as potent as SPICE. Together, these results suggest that principally 4 of the 11 residues that differ between SPICE and VCP partake in its enhanced function against human complement.
Yadav
Viveka Nand
VN
National Centre for Cell Science, Pune University Campus, Ganeshkhind, Pune 411007, India.
Pyaram
Kalyani
K
Mullick
Jayati
J
Sahu
Arvind
A
D000595:Amino Acid Sequence; D019943:Amino Acid Substitution / Q000235:genetics; D003179:Complement C3b / Q000037:antagonists & inhibitors; D015935:Complement C4b / Q000037:antagonists & inhibitors; D003165:Complement System Proteins / Q000276:immunology*; D006801:Humans; D008958:Models, Molecular; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D011485:Protein Binding; D016415:Sequence Alignment; D020349:Surface Plasmon Resonance; D014616:Vaccinia virus / Q000276:immunology*; D012901:Variola virus / Q000276:immunology*; D014764:Viral Proteins / Q000235:genetics* / Q000276:immunology* / Q000378:metabolism
D014764:Viral Proteins; C066459:complement-control protein, Vaccinia virus; D003179:Complement C3b; D015935:Complement C4b; D003165:Complement System Proteins